Cellares

We are pleased to announce that Kite Pharma will evaluate our automated cell therapy manufacturing platform, the Cell Shuttle. This collaboration with Kite Pharma, a Gilead Sciences Company, is a significant step in our mission to revolutionize cell therapy manufacturing. Together, we are pushing to bring the promise of cell therapies to more patients, faster. Read the full press release: https://lnkd.in/gF-MPFjX #CellTherapyManufacturing #IDMO #CellTherapy

In the Newsweek article, "The Many Faces of Oncology”, our Co-Founder & CEO, Fabian Gerlinghaus, highlights a significant issue: 'About 20 percent of patients are dying on the waitlist even though they are eligible for approved cell therapies because the industry is unable to meet patient demand.' This is a medical emergency. Learn more about how Cellares' Cell Shuttle platform integrates and automates the entire cell therapy manufacturing process, reducing labor and space requirements by 90% and processing 16 cell therapies simultaneously. This industry 4.0 approach aims to meet global patient demand for these life-saving cell therapies. Read now: https://lnkd.in/gsYX84RB For more Cellares coverage, check out the 🔗 link in the comments!

In a recent interview with Newsweek, our Co-Founder and CEO, Fabian Gerlinghaus shared his inspiring vision for the future of cell therapy manufacturing and how Cellares is leading the charge, transforming the industry, and enabling groundbreaking therapies to reach their full potential. Read the interview here: https://lnkd.in/graqe5uX #CellTherapyManufacturing #Biotech #IDMO

🎉 That’s a wrap for ISCT 2024! 🎉 We had a fantastic time at this year’s ISCT conference! Grateful for the opportunity to exchange ideas, showcase our latest work, and build new relationships. A big thank you to the organizers and attendees for an inspiring event. #ISCT24 #CellTherapyManufacturing

Nasdaq: Live From MarketSite! Kristina Ayanian recently interviewed our Co-Founder and CEO, Fabian Gerlinghaus on Nasdaq, Live From MarketSite where he discussed Cellares' $380M worldwide capacity reservation and supply agreement with Bristol Myers Squibb and the difference between an IDMO and a conventional CDMO. Watch more: https://lnkd.in/dhnqmhaF #NASDAQ #IDMO #CellTherapyManufacturing #LiveFromMarketSite

Cellares has been recognized as one of Fast Company’s Most Innovative Companies for 2024! We're committed to bring the promise of cell therapies to more patients, faster. Access to cell therapies can be life-saving for patients with serious ailments, but scaling these treatments has been a major challenge. At Cellares, we've created an ecosystem of integrated technologies for automated and high-throughput cell therapy manufacturing and quality control. The Cell Shuttle™ and Cell Q™ allow us to produce 10 times more cell therapies compared to conventional processes. Read the full article here: https://lnkd.in/gTB-Pjhq #CellTherapyManufacturing #FastCompany #celltherapy

Fabian Gerlinghaus, Co-Founder and CEO of Cellares, joins Nasdaq to celebrate their $380M collaboration with Bristol Myers Squibb for the manufacture of CAR T cell therapies. 👏 Watch more: https://lnkd.in/evVPP6zF

Join us at this year’s ISCT for an insightful panel discussion featuring our EVP of Commercialization, Arturo Araya, alongside industry leaders. The panel discussion, titled “Elevating Cell Therapy Manufacturing Using Industry 4.0: Unlocking Total Patient Access for Life-Saving Therapies,” will cover the transformative opportunities provided by adopting Industry 4.0 principles in cell therapy development and manufacturing. 🗓 Date: May 29, 2024 ⏰ Time: 10:45am - 11:45am PST Don’t miss out on the chance to learn from industry experts and discover how you can revolutionize your cell therapy manufacturing to meet total patient demand for these life-saving therapies. Visit https://lnkd.in/guaK9rBB to learn more about Cellares’ technologies. #ISCT24 #CellTherapyManufacturing #BioTech

Cellares and Bristol Myers Squibb have entered a $380M collaboration to enhance the manufacturing of CAR T cell therapies. Cellares Co-Founder & CEO Fabian Gerlinghaus talks about the terms of the agreement, its impact and future partnership plans on #NYSEFloorTalk with Judy Khan Shaw.

Fabian Gerlinghaus, our CEO and Co-Founder, was recently featured on NYSE’s Floor Talk with Judy Khan Shaw. In the interview, Fabian covers our recent $380M worldwide capacity reservation and supply agreement with Bristol Myers Squibb, key differences between an IDMO and conventional CDMOs, and Cell Q™, our flexible cGMP platform for high-throughput cell therapy quality control. Visit https://lnkd.in/guaK9rBB to learn more.